Project SCALE Tailored Digital Therapeutics for Neurological and Brain Disorder...
Project SCALE Tailored Digital Therapeutics for Neurological and Brain Disorders
Beats Therapeutics specialises in digital therapeutics for neurological and brain disorders. There are over a billion people worldwide living with a neurological or brain disorder. This has led to pressure on healthcare systems a...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto BeatsDigTherapeutics
Duración del proyecto: 36 meses
Fecha Inicio: 2019-08-20
Fecha Fin: 2022-08-31
Líder del proyecto
BEATS THERAPEUTICS LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Beats Therapeutics specialises in digital therapeutics for neurological and brain disorders. There are over a billion people worldwide living with a neurological or brain disorder. This has led to pressure on healthcare systems and payers to improve self-management and reduce long-term costs. The high risk and low approval rates of neuro-pharmaceuticals has led to billions of dollars of annual losses for the pharma industry. Many of these failures have been attributed to an insufficient understanding of the brain. We deliver tailored assessments and therapy's for neurological conditions with the aim to improve care and reduce costs while developing a greater understanding of neurological disease. Our core technology platform leverages data science and the advancements in hardware sensors to deliver cost effective daily assessments and individually tailored therapy to patients with neurological conditions. The innovation in this project is to scale up our current core technology platform in order to further deploy the technology in greater disease areas. Project Scale will allow us to enhance our core technology applicability to rapidly deploy disease specific technologies for pharmaceutical industry and payer industry while enhancing our global impact on patients’ lives.